Innate Pharma (IPHA) Net Cash Flow (2019 - 2025)

Innate Pharma (IPHA) has 7 years of Net Cash Flow data on file, last reported at -$61.4 million in Q4 2025.

• For the quarter ending Q4 2025, Net Cash Flow fell 345.34% year-over-year to -$61.4 million; the trailing twelve-month figure through Dec 2025 stood at -$75.2 million (down 15.61% YoY), and the FY2025 full-year result was -$45.9 million, down 1058.61% from the prior year.
• Net Cash Flow for Q4 2025 stood at -$61.4 million, down from -$13.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at -$1.4 million in Q2 2022 and bottomed at -$67.9 million in Q4 2021.
• The 5-year median for Net Cash Flow is -$29.3 million (2022), against an average of -$32.1 million.
• The widest annual swing landed in 2022, when Net Cash Flow soared 96.32%; it then slumped 875.83% in 2023.
• A 5-year view of Net Cash Flow shows it stood at -$67.9 million in 2021, then jumped by 68.48% to -$21.4 million in 2022, then slumped by 73.52% to -$37.1 million in 2023, then jumped by 62.88% to -$13.8 million in 2024, then tumbled by 345.34% to -$61.4 million in 2025.
• The last three Net Cash Flow figures came in at -$61.4 million (Q4 2025), -$13.8 million (Q4 2024), and -$37.1 million (Q4 2023), per Business Quant data.

Peer Comparison